Lexeo Therapeutics appoints Dr. Kyle Rasbach as CFO effective Dec 18, 2024

Lexeo Therapeutics, Inc.

Dr. Kyle Rasbach appointed CFO; CEO R. Nolan Townsend steps down as principal financial officer.
Initial base salary $480,000, discretionary bonus target 40%; receives 40,875 RSUs and options for 245,250 shares.
Rasbach previously CFO at Zentalis, portfolio manager at Eventide, and analyst at T. Rowe Price and Cowen.
Severance includes 12 months salary, COBRA, and potential equity acceleration; if over $120M financing, unvested equity may continue vesting 24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.